Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Adlai Nortye Group Ltd. has dosed the first patient in Australia and received U.S. FDA clearance to begin a global Phase I clinical trial of AN4035, a first-in-class CEACAM5-targeting antibody-drug conjugate armed with a pan-RAS(ON) inhibitor designed for tumor-selective delivery. The trial will evaluate AN4035's safety, pharmacokinetics, and preli…
Vor Bio announced the completion of enrollment in its global Phase 3 UPSTREAM MG trial evaluating telitacicept for generalized myasthenia gravis with topline results expected in the first half of 2027. The company also plans to begin a new Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding telitacicept's development across …
Del Taco, recognized as the #1 Best Fast Food Restaurant by USA TODAY's 10Best Reader's Choice Awards for 2026, is hosting a four-day promotional giveaway of free tacos at its Port St. Lucie location to thank customers and boost brand engagement. The celebration highlights Del Taco's commitment to quality ingredients and plans to introduce new menu…
Tonix Pharmaceuticals Holding Corp. announced the promotion of Thomas Englese to Chief Commercial Officer. Mr. Englese will lead sales, marketing, and commercial operations for TONMYA, a first-in-class treatment for fibromyalgia, and other acute migraine products. The company emphasizes its strong launch progress and aims to expand access and incre…
Monte Rosa Therapeutics announced that its collaborator Novartis has started a Phase 2 clinical trial for the investigational molecular glue degrader MRT-6160 (DDY391) targeting VAV1 in patients with Sjögren’s disease. Under their global exclusive license agreement, Monte Rosa will receive a $50 million milestone payment upon the first patient visi…
CalciMedica, a clinical-stage biopharmaceutical company focusing on CRAC channel inhibitors for inflammatory and cardiopulmonary diseases, announced its management will present and hold investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company is developing two main compounds: Auxora for in…
Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. Management will engage in a fireside chat and one-on-one investor meetings. The event highlights the company's ongoing commitment to developing innovative c…
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company focused on oral antiviral therapies, announced its presentation at the Morgan Stanley Global Healthcare Conference. The company will discuss its late-stage development programs including a Phase 3 regimen for hepatitis C and Phase 1 development for hepatitis E treatments.
Tilray Brands' craft beer subsidiary BrewDog has announced a five-year exclusive official beer partnership with Leicester Tigers, one of England’s premier rugby union clubs. Starting from the 2026-27 season, BrewDog will provide a full lineup of its beers at Leicester’s Welford Road Stadium, launching a new Tigers-branded ale and fan activations to…
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focusing on therapies for neuropathic corneal pain and anterior segment eye diseases, announced its participation in the Cantor Global Healthcare Conference. The event follows recent positive FDA Type D meeting feedback validating OKYO's regulatory and clinical pathway for its lead dru…
Nkarta, Inc. announced selection of three presentations at the ACR Convergence 2026 showcasing preliminary safety and clinical activity data for their NKX019 allogeneic CAR-NK cell therapy in autoimmune diseases. The presentations highlight promising safety profiles and initial efficacy signals in idiopathic inflammatory myopathy and systemic scler…
Beamr Imaging Ltd. has joined the VAST Cosmos Partner Program and collaborated with VAST Data and NVIDIA to deliver AI-powered video enhancement workflows aimed at broadcasters and content owners. Their solution enables upscaling and AI enhancement of lower-resolution video archives while optimizing storage and delivery costs, supporting monetizati…
X4 Pharmaceuticals announced a positive outcome from its FDA Type C meeting, with the FDA agreeing to reduce the sample size of its global 4WARD Phase 3 trial for mavorixafor treating chronic neutropenia from 176 to 126 participants. This reduction maintains adequate statistical power for key endpoints and a sufficient safety database, allowing fas…
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on CNS disorder treatments, announced management participation in three upcoming investor conferences in September 2026. The Company develops NMDA platform-based therapeutics for conditions including suicidal depression, chronic pain, and PTSD, with notable FDA designations fo…
Editas Medicine has appointed Dan Ory, M.D., an experienced biotechnology and cardiovascular medicine executive, as Chief Medical Officer. Dr. Ory will oversee clinical development strategy, particularly as the company prepares to advance EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, towards clinical trials. His expertise in…
NovaBridge Biosciences, a Nasdaq-listed global biotechnology company focused on oncology and ophthalmology therapeutic programs, announced the appointment of Martin Dewhurst to its Board of Directors as an independent director. Dewhurst brings over 30 years of leadership and governance experience in healthcare, serving on multiple boards globally a…
Daniel Masters, Co-Founder and Non-Executive Director of CoinShares PLC, has adopted a Rule 10b5-1 trading plan to sell up to approximately 3.6% of shares outstanding via scheduled transactions through December 31, 2027. Most sales relate to unwinding a 2023-2024 financing arrangement, with a limited reduction in his beneficial ownership to about 1…
BMO Capital Markets downgraded Amgen and BioNTech from Outperform to Market Perform, pointing to constrained near-term upside for both firms. For Amgen, loss-of-exclusivity pressures and mixed signals for its obesity candidate weighed on the call. For BioNTech, accelerating erosion of COVID vaccine sales, delayed de-risking for its cancer candidate…
ABM Industries Incorporated announced strong fiscal third quarter 2026 results with record quarterly revenue of $2.3 billion, a 4.2% increase year-over-year, driven by organic growth and acquisitions, notably in Manufacturing & Distribution and Aviation sectors. The company achieved a 19% increase in net income and adjusted net income, improved adj…
Ipsen shares fell after Barclays downgraded the stock and reduced its price target, highlighting accelerating generic erosion for Somatuline, the risk of a rival CAM2029 showing clinical superiority by late 2026 or early 2027, and a material reinvestment burden tied to later-stage pipeline launches. The downgrade compounded concerns already flagged…
A Nexus poll commissioned by BTG Pactual between September 4 and 7 indicates right-wing Senator Flavio Bolsonaro holds a one-point lead over President Luiz Inacio Lula da Silva in a simulated second-round runoff, while first-round voting preferences keep Lula ahead. The survey of 2,002 respondents reports a margin of error of 2 percentage points, m…
Lenovo (LNVGY) combines a broad hardware footprint with fast-growing infrastructure exposure via its ISG and services businesses. At a $52.0B market cap and $83.85 current price, the stock carries a premium multiple but offers asymmetric upside as hyperscale AI and data center demand accelerates. Liquidity and component-cost volatility are real ris…
Pharvaris announced positive topline results from its CHAPTER-3 pivotal Phase 3 trial demonstrating that deucrictibant extended-release (XR) tablet significantly reduces hereditary angioedema (HAE) attacks by 83% compared to placebo. The treatment was well tolerated, met all primary and secondary efficacy endpoints, and provides early and sustained…
Boston Scientific shares dropped 2.3% in pre-market trading after the company notified investors that the cyberattack discovered on August 25 is now expected to have a material impact on third-quarter and full-year 2026 results, and that it is unlikely to meet previously issued net sales growth and adjusted EPS targets. The announcement represents …
HSBC strategist Max Kettner argues that a series of structural changes since 2022 have left risk assets largely impervious to a succession of negative catalysts. He highlights stronger-than-expected earnings, a positive equity-bond correlation, and an expanded central bank toolkit among the main supports for market resilience, while pointing to the…
